[
  {
    "id": 42,
    "vaccine_id": 1,
    "trial_phase": "Phase I",
    "duration_months": 3,
    "participant_count": 45,
    "age_range_min": 216,
    "age_range_max": 660,
    "start_date": "2020-04-29T05:00:00.000Z",
    "end_date": "2020-07-29T05:00:00.000Z",
    "trial_identifier": "C4591001-1",
    "description": "First-in-human study evaluating safety, tolerability, and immunogenicity of BNT162b2",
    "monitoring_period_days": 7,
    "created_at": "2025-09-11T17:20:41.890Z"
  },
  {
    "id": 43,
    "vaccine_id": 1,
    "trial_phase": "Phase II/III",
    "duration_months": 6,
    "participant_count": 21744,
    "age_range_min": 192,
    "age_range_max": null,
    "start_date": "2020-07-27T05:00:00.000Z",
    "end_date": "2021-01-27T06:00:00.000Z",
    "trial_identifier": "C4591001-2",
    "description": "Pivotal efficacy trial demonstrating 95% efficacy against COVID-19. 21,744 participants received BNT162b2",
    "monitoring_period_days": 28,
    "created_at": "2025-09-11T17:20:41.891Z"
  },
  {
    "id": 44,
    "vaccine_id": 1,
    "trial_phase": "Phase III",
    "duration_months": 8,
    "participant_count": 2268,
    "age_range_min": 144,
    "age_range_max": 191,
    "start_date": "2020-10-15T05:00:00.000Z",
    "end_date": "2021-06-15T05:00:00.000Z",
    "trial_identifier": "C4591001-3",
    "description": "Adolescent trial (12-15 years) showing 100% efficacy and robust antibody response",
    "monitoring_period_days": 14,
    "created_at": "2025-09-11T17:20:41.892Z"
  },
  {
    "id": 45,
    "vaccine_id": 2,
    "trial_phase": "Phase I",
    "duration_months": 4,
    "participant_count": 45,
    "age_range_min": 216,
    "age_range_max": 660,
    "start_date": "2020-03-16T05:00:00.000Z",
    "end_date": "2020-07-16T05:00:00.000Z",
    "trial_identifier": "mRNA-1273-P101",
    "description": "First-in-human dose-escalation study of mRNA-1273",
    "monitoring_period_days": 28,
    "created_at": "2025-09-11T17:20:41.919Z"
  },
  {
    "id": 46,
    "vaccine_id": 2,
    "trial_phase": "Phase III",
    "duration_months": 6,
    "participant_count": 15210,
    "age_range_min": 216,
    "age_range_max": null,
    "start_date": "2020-07-27T05:00:00.000Z",
    "end_date": "2021-01-27T06:00:00.000Z",
    "trial_identifier": "COVE",
    "description": "Pivotal efficacy trial (COVE study) demonstrating 94.1% efficacy against COVID-19",
    "monitoring_period_days": 28,
    "created_at": "2025-09-11T17:20:41.919Z"
  },
  {
    "id": 3,
    "vaccine_id": 3,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 11082,
    "age_range_min": 12,
    "age_range_max": 60,
    "start_date": "1978-01-01T06:00:00.000Z",
    "end_date": "1980-01-01T06:00:00.000Z",
    "trial_identifier": "MMR-78-001",
    "description": "Large-scale efficacy study of combined measles, mumps, and rubella vaccine in children and adults",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T15:31:50.900Z"
  },
  {
    "id": 5,
    "vaccine_id": 4,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 2500,
    "age_range_min": 2,
    "age_range_max": 84,
    "start_date": "1995-01-15T06:00:00.000Z",
    "end_date": "1998-01-15T06:00:00.000Z",
    "trial_identifier": "DTaP-001",
    "description": "Multicenter trial comparing DTaP with whole-cell DTP vaccine efficacy and safety",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.397Z"
  },
  {
    "id": 20,
    "vaccine_id": 4,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 2500,
    "age_range_min": 2,
    "age_range_max": 84,
    "start_date": "1995-01-15T06:00:00.000Z",
    "end_date": "1998-01-15T06:00:00.000Z",
    "trial_identifier": "DTaP-001",
    "description": "Multicenter trial comparing DTaP with whole-cell DTP vaccine efficacy and safety",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.637Z"
  },
  {
    "id": 36,
    "vaccine_id": 5,
    "trial_phase": "Phase III",
    "duration_months": 12,
    "participant_count": 147,
    "age_range_min": 0,
    "age_range_max": 120,
    "start_date": "1985-01-01T06:00:00.000Z",
    "end_date": "1986-01-01T06:00:00.000Z",
    "trial_identifier": "RECOMBIVAX-HB-001",
    "description": "434 doses of RECOMBIVAX HB, 5 mcg, administered to 147 healthy infants and children (up to 10 years) monitored for 5 days after each dose. Injection site reactions: 0.2%, systemic adverse reactions: 10.4%",
    "monitoring_period_days": 5,
    "created_at": "2025-09-11T17:09:16.160Z"
  },
  {
    "id": 37,
    "vaccine_id": 5,
    "trial_phase": "Phase III",
    "duration_months": 18,
    "participant_count": 1252,
    "age_range_min": 132,
    "age_range_max": null,
    "start_date": "1985-06-01T05:00:00.000Z",
    "end_date": "1987-01-01T06:00:00.000Z",
    "trial_identifier": "RECOMBIVAX-HB-002",
    "description": "3258 doses of RECOMBIVAX HB, 10 mcg, administered to 1252 healthy adults monitored for 5 days after each dose. Injection site reactions: 17%, systemic adverse reactions: 15%",
    "monitoring_period_days": 5,
    "created_at": "2025-09-11T17:09:16.162Z"
  },
  {
    "id": 38,
    "vaccine_id": 5,
    "trial_phase": "Phase II",
    "duration_months": 6,
    "participant_count": 895,
    "age_range_min": 132,
    "age_range_max": 228,
    "start_date": "1984-09-01T05:00:00.000Z",
    "end_date": "1985-03-01T06:00:00.000Z",
    "trial_identifier": "RECOMBIVAX-HB-003",
    "description": "Three-dose regimen (5 mcg) vs two-dose regimen (10 mcg) comparison study in adolescents. Overall frequency of adverse reactions was generally similar between regimens.",
    "monitoring_period_days": 5,
    "created_at": "2025-09-11T17:09:16.164Z"
  },
  {
    "id": 6,
    "vaccine_id": 6,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 8000,
    "age_range_min": 2,
    "age_range_max": 60,
    "start_date": "1987-03-01T06:00:00.000Z",
    "end_date": "1989-03-01T06:00:00.000Z",
    "trial_identifier": "HIB-001",
    "description": "Efficacy trial of Haemophilus b conjugate vaccine in infants and children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.399Z"
  },
  {
    "id": 21,
    "vaccine_id": 6,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 8000,
    "age_range_min": 2,
    "age_range_max": 60,
    "start_date": "1987-03-01T06:00:00.000Z",
    "end_date": "1989-03-01T06:00:00.000Z",
    "trial_identifier": "HIB-001",
    "description": "Efficacy trial of Haemophilus b conjugate vaccine in infants and children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.639Z"
  },
  {
    "id": 7,
    "vaccine_id": 8,
    "trial_phase": "Phase III",
    "duration_months": 60,
    "participant_count": 4000,
    "age_range_min": 11,
    "age_range_max": 64,
    "start_date": "2000-05-01T05:00:00.000Z",
    "end_date": "2005-05-01T05:00:00.000Z",
    "trial_identifier": "TDAP-002",
    "description": "Safety and immunogenicity study of reduced antigen diphtheria-tetanus-pertussis vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.400Z"
  },
  {
    "id": 22,
    "vaccine_id": 8,
    "trial_phase": "Phase III",
    "duration_months": 60,
    "participant_count": 4000,
    "age_range_min": 11,
    "age_range_max": 64,
    "start_date": "2000-05-01T05:00:00.000Z",
    "end_date": "2005-05-01T05:00:00.000Z",
    "trial_identifier": "TDAP-002",
    "description": "Safety and immunogenicity study of reduced antigen diphtheria-tetanus-pertussis vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.641Z"
  },
  {
    "id": 8,
    "vaccine_id": 10,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 7500,
    "age_range_min": 10,
    "age_range_max": 25,
    "start_date": "2007-09-01T05:00:00.000Z",
    "end_date": "2010-09-01T05:00:00.000Z",
    "trial_identifier": "MENB-001",
    "description": "Controlled study of meningococcal group B vaccine effectiveness",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.402Z"
  },
  {
    "id": 23,
    "vaccine_id": 10,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 7500,
    "age_range_min": 10,
    "age_range_max": 25,
    "start_date": "2007-09-01T05:00:00.000Z",
    "end_date": "2010-09-01T05:00:00.000Z",
    "trial_identifier": "MENB-001",
    "description": "Controlled study of meningococcal group B vaccine effectiveness",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.643Z"
  },
  {
    "id": 9,
    "vaccine_id": 12,
    "trial_phase": "Phase III",
    "duration_months": 48,
    "participant_count": 18644,
    "age_range_min": 15,
    "age_range_max": 25,
    "start_date": "2004-05-01T05:00:00.000Z",
    "end_date": "2008-05-01T05:00:00.000Z",
    "trial_identifier": "HPV-007",
    "description": "PATRICIA study: efficacy and safety of HPV-16/18 AS04-adjuvanted vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.403Z"
  },
  {
    "id": 24,
    "vaccine_id": 12,
    "trial_phase": "Phase III",
    "duration_months": 48,
    "participant_count": 18644,
    "age_range_min": 15,
    "age_range_max": 25,
    "start_date": "2004-05-01T05:00:00.000Z",
    "end_date": "2008-05-01T05:00:00.000Z",
    "trial_identifier": "HPV-007",
    "description": "PATRICIA study: efficacy and safety of HPV-16/18 AS04-adjuvanted vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.644Z"
  },
  {
    "id": 10,
    "vaccine_id": 14,
    "trial_phase": "Phase III",
    "duration_months": 60,
    "participant_count": 1083,
    "age_range_min": 0,
    "age_range_max": 70,
    "start_date": "1982-01-01T06:00:00.000Z",
    "end_date": "1987-01-01T06:00:00.000Z",
    "trial_identifier": "HEPB-002",
    "description": "Multicenter trial of recombinant hepatitis B vaccine efficacy and safety",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.405Z"
  },
  {
    "id": 25,
    "vaccine_id": 14,
    "trial_phase": "Phase III",
    "duration_months": 60,
    "participant_count": 1083,
    "age_range_min": 0,
    "age_range_max": 70,
    "start_date": "1982-01-01T06:00:00.000Z",
    "end_date": "1987-01-01T06:00:00.000Z",
    "trial_identifier": "HEPB-002",
    "description": "Multicenter trial of recombinant hepatitis B vaccine efficacy and safety",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.646Z"
  },
  {
    "id": 11,
    "vaccine_id": 19,
    "trial_phase": "Phase III",
    "duration_months": 54,
    "participant_count": 14215,
    "age_range_min": 16,
    "age_range_max": 26,
    "start_date": "2007-12-01T06:00:00.000Z",
    "end_date": "2012-06-01T05:00:00.000Z",
    "trial_identifier": "V503-001",
    "description": "Efficacy study of 9-valent HPV vaccine in young women",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.407Z"
  },
  {
    "id": 26,
    "vaccine_id": 19,
    "trial_phase": "Phase III",
    "duration_months": 54,
    "participant_count": 14215,
    "age_range_min": 16,
    "age_range_max": 26,
    "start_date": "2007-12-01T06:00:00.000Z",
    "end_date": "2012-06-01T05:00:00.000Z",
    "trial_identifier": "V503-001",
    "description": "Efficacy study of 9-valent HPV vaccine in young women",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.648Z"
  },
  {
    "id": 12,
    "vaccine_id": 20,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 40119,
    "age_range_min": 1,
    "age_range_max": 16,
    "start_date": "1992-11-01T06:00:00.000Z",
    "end_date": "1995-11-01T06:00:00.000Z",
    "trial_identifier": "HEPA-001",
    "description": "Large-scale efficacy trial of hepatitis A vaccine in children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.409Z"
  },
  {
    "id": 27,
    "vaccine_id": 20,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 40119,
    "age_range_min": 1,
    "age_range_max": 16,
    "start_date": "1992-11-01T06:00:00.000Z",
    "end_date": "1995-11-01T06:00:00.000Z",
    "trial_identifier": "HEPA-001",
    "description": "Large-scale efficacy trial of hepatitis A vaccine in children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.649Z"
  },
  {
    "id": 13,
    "vaccine_id": 24,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 1500,
    "age_range_min": 2,
    "age_range_max": 18,
    "start_date": "1978-01-01T06:00:00.000Z",
    "end_date": "1980-01-01T06:00:00.000Z",
    "trial_identifier": "IPV-001",
    "description": "Safety and immunogenicity trial of enhanced inactivated poliovirus vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.411Z"
  },
  {
    "id": 28,
    "vaccine_id": 24,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 1500,
    "age_range_min": 2,
    "age_range_max": 18,
    "start_date": "1978-01-01T06:00:00.000Z",
    "end_date": "1980-01-01T06:00:00.000Z",
    "trial_identifier": "IPV-001",
    "description": "Safety and immunogenicity trial of enhanced inactivated poliovirus vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.651Z"
  },
  {
    "id": 39,
    "vaccine_id": 25,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 1482,
    "age_range_min": 12,
    "age_range_max": 15,
    "start_date": "1978-03-01T06:00:00.000Z",
    "end_date": "1981-03-01T06:00:00.000Z",
    "trial_identifier": "MMR-001",
    "description": "Pre-licensure efficacy study of M-M-R II in children 12-15 months. Efficacy: Measles 95%, Mumps 96%, Rubella 91%",
    "monitoring_period_days": 42,
    "created_at": "2025-09-11T17:20:41.850Z"
  },
  {
    "id": 40,
    "vaccine_id": 25,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 956,
    "age_range_min": 48,
    "age_range_max": 72,
    "start_date": "1979-09-01T05:00:00.000Z",
    "end_date": "1981-09-01T05:00:00.000Z",
    "trial_identifier": "MMR-002",
    "description": "Second dose efficacy study in school-age children. Enhanced immune response and long-term protection demonstrated",
    "monitoring_period_days": 42,
    "created_at": "2025-09-11T17:20:41.855Z"
  },
  {
    "id": 41,
    "vaccine_id": 25,
    "trial_phase": "Phase II",
    "duration_months": 12,
    "participant_count": 643,
    "age_range_min": 12,
    "age_range_max": 24,
    "start_date": "1976-01-01T06:00:00.000Z",
    "end_date": "1977-01-01T06:00:00.000Z",
    "trial_identifier": "MMR-003",
    "description": "Safety and immunogenicity study comparing M-M-R II with separate measles, mumps, and rubella vaccines",
    "monitoring_period_days": 42,
    "created_at": "2025-09-11T17:20:41.857Z"
  },
  {
    "id": 34,
    "vaccine_id": 28,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 147,
    "age_range_min": 0,
    "age_range_max": 120,
    "start_date": "1998-01-01T06:00:00.000Z",
    "end_date": "2000-01-01T06:00:00.000Z",
    "trial_identifier": "PEDIARIX-001",
    "description": "434 doses of RECOMBIVAX HB (5 mcg) administered to 147 healthy infants and children (up to 10 years) monitored for 5 days after each dose. Injection site reactions: 0.2%, systemic adverse reactions: 10.4%",
    "monitoring_period_days": 5,
    "created_at": "2025-09-11T16:58:26.254Z"
  },
  {
    "id": 35,
    "vaccine_id": 28,
    "trial_phase": "Phase III",
    "duration_months": 12,
    "participant_count": 1252,
    "age_range_min": 132,
    "age_range_max": null,
    "start_date": "1999-01-01T06:00:00.000Z",
    "end_date": "2000-01-01T06:00:00.000Z",
    "trial_identifier": "PEDIARIX-002",
    "description": "3258 doses of RECOMBIVAX HB (10 mcg) administered to 1252 healthy adults monitored for 5 days after each dose. Injection site reactions: 17%, systemic adverse reactions: 15%",
    "monitoring_period_days": 5,
    "created_at": "2025-09-11T16:58:26.258Z"
  },
  {
    "id": 15,
    "vaccine_id": 30,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 86000,
    "age_range_min": 2,
    "age_range_max": 84,
    "start_date": "2006-01-01T06:00:00.000Z",
    "end_date": "2009-01-01T06:00:00.000Z",
    "trial_identifier": "PCV13-001",
    "description": "Efficacy and safety study of 13-valent pneumococcal conjugate vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.413Z"
  },
  {
    "id": 30,
    "vaccine_id": 30,
    "trial_phase": "Phase III",
    "duration_months": 36,
    "participant_count": 86000,
    "age_range_min": 2,
    "age_range_max": 84,
    "start_date": "2006-01-01T06:00:00.000Z",
    "end_date": "2009-01-01T06:00:00.000Z",
    "trial_identifier": "PCV13-001",
    "description": "Efficacy and safety study of 13-valent pneumococcal conjugate vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.653Z"
  },
  {
    "id": 16,
    "vaccine_id": 31,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 63225,
    "age_range_min": 6,
    "age_range_max": 32,
    "start_date": "2003-10-01T05:00:00.000Z",
    "end_date": "2005-10-01T05:00:00.000Z",
    "trial_identifier": "ROTA-036",
    "description": "Large-scale efficacy and safety trial of rotavirus vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.414Z"
  },
  {
    "id": 31,
    "vaccine_id": 31,
    "trial_phase": "Phase III",
    "duration_months": 24,
    "participant_count": 63225,
    "age_range_min": 6,
    "age_range_max": 32,
    "start_date": "2003-10-01T05:00:00.000Z",
    "end_date": "2005-10-01T05:00:00.000Z",
    "trial_identifier": "ROTA-036",
    "description": "Large-scale efficacy and safety trial of rotavirus vaccine",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.654Z"
  },
  {
    "id": 17,
    "vaccine_id": 33,
    "trial_phase": "Phase III",
    "duration_months": 48,
    "participant_count": 15411,
    "age_range_min": 50,
    "age_range_max": null,
    "start_date": "2010-09-01T05:00:00.000Z",
    "end_date": "2014-09-01T05:00:00.000Z",
    "trial_identifier": "ZOSTER-006",
    "description": "ZOE-50 study: efficacy of recombinant zoster vaccine in adults ≥50 years",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.416Z"
  },
  {
    "id": 32,
    "vaccine_id": 33,
    "trial_phase": "Phase III",
    "duration_months": 48,
    "participant_count": 15411,
    "age_range_min": 50,
    "age_range_max": null,
    "start_date": "2010-09-01T05:00:00.000Z",
    "end_date": "2014-09-01T05:00:00.000Z",
    "trial_identifier": "ZOSTER-006",
    "description": "ZOE-50 study: efficacy of recombinant zoster vaccine in adults ≥50 years",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.655Z"
  },
  {
    "id": 18,
    "vaccine_id": 36,
    "trial_phase": "Phase III",
    "duration_months": 84,
    "participant_count": 11000,
    "age_range_min": 12,
    "age_range_max": 144,
    "start_date": "1986-01-01T06:00:00.000Z",
    "end_date": "1993-01-01T06:00:00.000Z",
    "trial_identifier": "VAR-001",
    "description": "Long-term efficacy study of varicella vaccine in healthy children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:06.417Z"
  },
  {
    "id": 33,
    "vaccine_id": 36,
    "trial_phase": "Phase III",
    "duration_months": 84,
    "participant_count": 11000,
    "age_range_min": 12,
    "age_range_max": 144,
    "start_date": "1986-01-01T06:00:00.000Z",
    "end_date": "1993-01-01T06:00:00.000Z",
    "trial_identifier": "VAR-001",
    "description": "Long-term efficacy study of varicella vaccine in healthy children",
    "monitoring_period_days": null,
    "created_at": "2025-09-11T16:42:36.656Z"
  }
]